Calidi (CLDI) CSO Fernandez Santidrian Receives 16,000 Options

What Happened

• Antonio Fernandez Santidrian, Chief Scientific Officer of Calidi Biotherapeutics (CLDI), received a grant of 16,000 incentive stock options (derivative securities) on August 17, 2026.
• The options carry an exercise price of $1.36 per share (equal to the closing market price on the grant date). At that strike, exercising all options would cost $21,760 in total. This was a compensation award (not an open-market purchase or sale) and was granted under the issuer’s 2023 Equity Incentive Plan.

Key Details

• Transaction date: 2026-08-17 (reported on Form 4 filed 2026-08-19; filing appears timely — within the usual 2-business-day window).
• Transaction type: A = Award/Grant (derivative instrument — incentive stock options).
• Quantity and price: 16,000 options; exercise price $1.36 per share.
• Vesting: 25% vests on the one-year anniversary (08/17/2027); remaining 75% vests in 1/36th monthly installments thereafter (subject to continued service). Effectively a multi-year vesting schedule.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: Grant made under the 2023 Equity Incentive Plan and exempt under Rule 16b-3. Footnote also notes this filing does not include previously granted options to the reporting person.
• Exhibit: Exhibit 24 (Power of Attorney) attached to the filing.

Context

• These were option grants (compensation), not an immediate purchase or sale of shares; no exercise or sale was reported.
• Because the exercise price equals the market close on the grant date, there was no immediate in-the-money gain at grant. Vesting is time-based and contingent on continued service, so the options only become exercisable over the coming years.
• Such plan-based awards are common for executives and are disclosed under Rule 16b-3; they do not by themselves indicate the insider’s view of the company’s stock.